$HCSG
HEALTHCARE SERVICES GROUP INC Stock $hcsg

$hcsg Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000073101224000065 Filed on April 26, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$426.3M	$423.4M
YoY Change	1.76%	1.49%
Cost Of Revenue	$384.7M	$358.7M
YoY Change	4.63%	-0.63%
Gross Profit	$41.55M	$64.72M
YoY Change	-18.86%	15.06%
Gross Profit Margin	9.75%	15.29%
Selling, General & Admin	$44.44M	$51.01M
YoY Change	7.26%	27.38%
% of Gross Profit	106.96%	78.82%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$3.000M	$3.531M
YoY Change	-16.55%	-5.08%
% of Gross Profit	7.22%	5.46%
Operating Expenses	$44.44M	$51.01M
YoY Change	7.26%	27.38%
Operating Profit	-$2.891M	$13.71M
YoY Change	-129.58%	-15.39%
Interest Expense	-$1.716M	$1.904M
YoY Change	-204.91%	-208.74%
% of Operating Profit		13.89%
Other Income/Expense, Net	$905.0K	$5.699M
YoY Change
Pretax Income	-$1.986M	$21.31M
YoY Change	-117.41%	21.41%
Income Tax	-$198.0K	$6.005M
% Of Pretax Income		28.17%
Net Earnings	-$1.788M	$15.31M
YoY Change	-120.8%	20.7%
Net Earnings / Revenue	-0.42%	3.62%
Basic Earnings Per Share	-$0.02	$0.21
Diluted Earnings Per Share	-$0.02	$0.21
COMMON SHARES
Basic Shares Outstanding	73.65M shares	73.58M shares
Diluted Shares Outstanding	73.85M shares	74.06M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$105.7M	$104.9M
YoY Change	-13.23%	-6.45%
Cash & Equivalents	$26.43M	$29.29M
Short-Term Investments	$79.30M	$75.62M
Other Short-Term Assets	$68.60M	$50.33M
YoY Change	161.06%	99.8%
Inventory	$17.86M	$18.04M
Prepaid Expenses	$25.77M	$25.63M
Receivables	$398.9M	$407.1M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$573.2M	$580.4M
YoY Change	4.39%	13.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$29.84M	$29.19M
YoY Change	10.8%	24.74%
Goodwill	$75.53M	$75.53M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.505M	$84.00M
YoY Change	-93.17%	10953.16%
Total Long-Term Assets	$226.5M	$223.5M
YoY Change	6.5%	6.9%
TOTAL ASSETS
Total Short-Term Assets	$573.2M	$580.4M
Total Long-Term Assets	$226.5M	$223.5M
Total Assets	$799.7M	$803.9M
YoY Change	4.98%	11.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$72.22M	$72.92M
YoY Change	10.05%	13.31%
Accrued Expenses	$21.59M	$83.41M
YoY Change	-73.42%	35.72%
Deferred Revenue
YoY Change
Short-Term Debt	$30.00M	$40.00M
YoY Change	-25.0%	14.29%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$209.5M	$209.4M
YoY Change	10.45%	29.11%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$724.0K	$119.9M
YoY Change	-99.4%	1759.86%
Total Long-Term Liabilities	$724.0K	$119.9M
YoY Change	-99.4%	1759.86%
TOTAL LIABILITIES
Total Short-Term Liabilities	$209.5M	$209.4M
Total Long-Term Liabilities	$724.0K	$119.9M
Total Liabilities	$210.2M	$329.3M
YoY Change	-32.45%	95.3%
SHAREHOLDERS EQUITY
Retained Earnings	$198.6M	$200.4M
YoY Change	12.97%	19.85%
Common Stock	$314.9M	$312.8M
YoY Change	2.71%	2.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$471.4M	$474.6M
YoY Change
Total Liabilities & Shareholders Equity	$799.7M	$803.9M
YoY Change	4.98%	11.78%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$1.788M	$15.31M
YoY Change	-120.8%	20.7%
Depreciation, Depletion And Amortization	$3.000M	$3.531M
YoY Change	-16.55%	-5.08%
Cash From Operating Activities	$16.32M	-$26.03M
YoY Change	120.44%	59.81%
INVESTING ACTIVITIES
Capital Expenditures	$1.312M	$2.198M
YoY Change	20.7%	117.62%
Acquisitions
YoY Change
Other Investing Activities	-$26.44M	$13.91M
YoY Change	-2316.51%	5111.24%
Cash From Investing Activities	-$27.76M	$11.72M
YoY Change	-26283.96%	-1676.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-13.00M	13.97M
YoY Change	-360.0%	102.26%
NET CHANGE
Cash From Operating Activities	16.32M	-26.03M
Cash From Investing Activities	-27.76M	11.72M
Cash From Financing Activities	-13.00M	13.97M
Net Change In Cash	-24.44M	-347.0K
YoY Change	-295.35%	-96.57%
FREE CASH FLOW
Cash From Operating Activities	$16.32M	-$26.03M
Capital Expenditures	$1.312M	$2.198M
Free Cash Flow	$15.01M	-$28.23M
YoY Change	137.6%	63.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	25631000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	22247000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	580414000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	571696000	usd
CY2024Q1	hcsg	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	29190000	usd
CY2023Q4	hcsg	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	28774000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	75529000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	75529000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	37228000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	36557000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	11456000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12127000	usd
CY2024Q1	us-gaap	Allowance For Notes And Loans Receivable Noncurrent AllowanceForNotesAndLoansReceivableNoncurrent	3720000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	72916000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	83224000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	38338000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	56142000	usd
CY2023Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	7201000	usd
CY2024Q1	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	1293000	usd
CY2023Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	1501000	usd
CY2024Q1	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	23138000	usd
CY2023Q4	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	22681000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	209375000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	216928000	usd
CY2024Q1	us-gaap	Workers Compensation Liability Noncurrent WorkersCompensationLiabilityNoncurrent	62796000	usd
CY2023Q4	us-gaap	Workers Compensation Liability Noncurrent WorkersCompensationLiabilityNoncurrent	61697000	usd
CY2024Q1	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	44271000	usd
CY2023Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	41186000	usd
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	37749000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	474581000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	456616000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	803880000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	790652000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	423433000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	417230000	usd
CY2023Q4	us-gaap	Allowance For Notes And Loans Receivable Noncurrent AllowanceForNotesAndLoansReceivableNoncurrent	4449000	usd
CY2024Q1	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	23287000	usd
CY2023Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	24832000	usd
CY2024Q1	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	44269000	usd
CY2023Q4	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	40812000	usd
CY2024Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	35434000	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	35226000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4301000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1656000	usd
CY2024Q1	us-gaap	Assets Assets	803880000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	21931000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	21179000	usd
CY2024Q1	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	40000000	usd
CY2023Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	25000000	usd
CY2024Q1	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	11759000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10590000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11235000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2267000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2990000	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	76533000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	76329000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73646000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73341000	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	765000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	763000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	312080000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	310436000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	200381000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	185010000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2172000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1844000	usd
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	2887000	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	2988000	shares
CY2024Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	36473000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://hcsgcorp.com/20240331#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://hcsgcorp.com/20240331#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	91868000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	87250000	usd
CY2024Q1	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	407140000	usd
CY2023Q4	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	383509000	usd
CY2024Q1	us-gaap	Other Inventory OtherInventory	18042000	usd
CY2023Q4	us-gaap	Other Inventory OtherInventory	18479000	usd
CY2023Q4	us-gaap	Assets Assets	790652000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	358911000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	362379000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	46911000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	40047000	usd
CY2024Q1	hcsg	Investment Income And Other InvestmentIncomeAndOther	5699000	usd
CY2023Q1	hcsg	Investment Income And Other InvestmentIncomeAndOther	3102000	usd
CY2024Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1996000	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1751000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	21314000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	16155000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6005000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4484000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	15309000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	11671000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.21
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.16
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.21
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.16
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73926000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74497000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74055000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74518000	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	15309000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	11671000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-328000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1207000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	14981000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	12878000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3531000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3720000	usd
CY2024Q1	hcsg	Accounts And Financing Receivable Credit Loss Expense Reversal AccountsAndFinancingReceivableCreditLossExpenseReversal	4921000	usd
CY2023Q1	hcsg	Accounts And Financing Receivable Credit Loss Expense Reversal AccountsAndFinancingReceivableCreditLossExpenseReversal	6907000	usd
CY2024Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-121000	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	43000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2484000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2058000	usd
CY2024Q1	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	459000	usd
CY2023Q1	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	533000	usd
CY2024Q1	hcsg	Unrealized Gain Loss On Securities Related To Deferred Compensation Fund UnrealizedGainLossOnSecuritiesRelatedToDeferredCompensationFund	4110000	usd
CY2023Q1	hcsg	Unrealized Gain Loss On Securities Related To Deferred Compensation Fund UnrealizedGainLossOnSecuritiesRelatedToDeferredCompensationFund	1502000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	1308000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	336000	usd
CY2024Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-180000	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-128000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	27007000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	20633000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-438000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-935000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3350000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4076000	usd
CY2024Q1	hcsg	Increase Decrease In Deferred Compensation Funding IncreaseDecreaseInDeferredCompensationFunding	-653000	usd
CY2023Q1	hcsg	Increase Decrease In Deferred Compensation Funding IncreaseDecreaseInDeferredCompensationFunding	-683000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-13493000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-6422000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	-16815000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	-19766000	usd
CY2024Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	2070000	usd
CY2023Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	2136000	usd
CY2024Q1	us-gaap	Increase Decrease In Workers Compensation Liabilities IncreaseDecreaseInWorkersCompensationLiabilities	1556000	usd
CY2023Q1	us-gaap	Increase Decrease In Workers Compensation Liabilities IncreaseDecreaseInWorkersCompensationLiabilities	2366000	usd
CY2024Q1	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	3394000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	713000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26033000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16290000	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	25000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	57000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2198000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1010000	usd
CY2024Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	2750000	usd
CY2023Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	16639000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	210000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	11716000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-743000	usd
CY2024Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2223000	usd
CY2024Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	15000000	usd
CY2023Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	10000000	usd
CY2024Q1	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	1030000	usd
CY2023Q1	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	870000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13970000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6907000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-347000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10126000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54330000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26279000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53983000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16153000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	456616000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	15309000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-328000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-1030000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2444000	usd
CY2024Q1	hcsg	Stock Issued During Period Value Treasury Stock Reissued Deferred Compensation Net StockIssuedDuringPeriodValueTreasuryStockReissuedDeferredCompensationNet	519000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	989000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	62000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	474581000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	418279000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	11671000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1207000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-870000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1973000	usd
CY2023Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	2223000	usd
CY2024Q1	hcsg	Revenue From Contract With Customer Renewal Term RevenueFromContractWithCustomerRenewalTerm	P1Y
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing financial statements in conformity with U.S. GAAP, estimates and assumptions are made that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results could differ from those estimates. Significant estimates are used in determining, but are not limited to, the Company’s allowance for doubtful accounts, accrued insurance claims, deferred taxes and reviews for potential impairment. The estimates are based upon various factors including current and historical trends, as well as other pertinent industry and regulatory authority information. Management regularly evaluates this information to determine if it is necessary to update the basis for its estimates and to adjust for known changes.</span></div>
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29288000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16153000	usd
CY2024Q1	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	24695000	usd
CY2023Q1	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	0	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53983000	usd
CY2024Q1	us-gaap	Contract With Customer Timing Of Satisfaction Of Performance Obligation And Payment ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment	The Company’s payment terms with customers on promissory notes can vary based on several factors and the circumstances of each promissory note, however most promissory notes mature over 1 to 4 years. Similar to accounts receivable, each reporting period the Company evaluates the collectability of outstanding notes receivable balances and records an allowance for doubtful accounts representing an estimate of future expected credit losses
CY2024Q1	hcsg	Period Of Amortization Of Inventories And Supplies PeriodOfAmortizationOfInventoriesAndSupplies	P24M
CY2023Q1	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2024Q1	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial instruments that are subject to credit risk are cash and cash equivalents, restricted cash equivalents, marketable securities, deferred compensation funding and accounts and notes receivable. At March 31, 2024, the majority of the Company’s cash and cash equivalents, restricted cash equivalents and marketable securities were held in two large financial institutions located in the United States. At December 31, 2023, the majority were held in one large financial institution located in the United States. The Company’s marketable securities are fixed income investments which are highly liquid and can be readily purchased or sold through established markets. The Company’s deferred compensation funding consists of fund and money market investments all of which are highly liquid and held in a trust account.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s customers are concentrated in the healthcare industry and are primarily providers of long-term care. The revenues of many of the Company’s customers are highly reliant on Medicare, Medicaid and third party payors’ reimbursement funding rates. New legislation or changes in existing regulations could directly impact the governmental reimbursement programs in which the Company’s customers participate. As a result, the Company may not realize the full effects such programs may have on the Company’s customers until such new legislation or changes in existing regulations are fully implemented and governmental agencies issue applicable regulations or guidance.</span></div>
CY2024Q1	hcsg	Concentration Risk Numberof Financial Institutions Holding Cashand Cash Equivalentsand Marketable Securities ConcentrationRiskNumberofFinancialInstitutionsHoldingCashandCashEquivalentsandMarketableSecurities	2	institution
CY2023Q4	hcsg	Concentration Risk Numberof Financial Institutions Holding Cashand Cash Equivalentsand Marketable Securities ConcentrationRiskNumberofFinancialInstitutionsHoldingCashandCashEquivalentsandMarketableSecurities	1	institution
CY2024Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior period line items in the Consolidated Statements of Stockholders’ Equity have been revised to conform with current period presentation.</span></div>
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	362379000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	16155000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4484000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	11671000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.16
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.16
CY2024Q1	hcsg	Revenue From Contract With Customer Renewal Term RevenueFromContractWithCustomerRenewalTerm	P1Y
CY2024Q1	us-gaap	Revenue Performance Obligation Description Of Timing RevenuePerformanceObligationDescriptionOfTiming	The Company’s contracts with customers typically provide for an initial term of one year, with renewable one year service terms, cancellable by either party upon 30 to 90 days’ notice after an initial period of 60 to 120 days.
CY2024Q1	hcsg	Revenue From Contract With Customer Initial Term RevenueFromContractWithCustomerInitialTerm	P1Y
CY2024Q1	hcsg	Revenue From Contract With Customer Renewal Term RevenueFromContractWithCustomerRenewalTerm	P1Y
CY2024Q1	hcsg	Accounts Notes Loansand Financing Receivable Gross Current AccountsNotesLoansandFinancingReceivableGrossCurrent	499008000	usd
CY2023Q4	hcsg	Accounts Notes Loansand Financing Receivable Gross Current AccountsNotesLoansandFinancingReceivableGrossCurrent	470759000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	91868000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	87250000	usd
CY2024Q1	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	407140000	usd
CY2023Q4	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	383509000	usd
CY2024Q1	us-gaap	Notes And Loans Receivable Gross Noncurrent NotesAndLoansReceivableGrossNoncurrent	27007000	usd
CY2023Q4	us-gaap	Notes And Loans Receivable Gross Noncurrent NotesAndLoansReceivableGrossNoncurrent	29281000	usd
CY2024Q1	us-gaap	Allowance For Notes And Loans Receivable Noncurrent AllowanceForNotesAndLoansReceivableNoncurrent	3720000	usd
CY2023Q4	us-gaap	Allowance For Notes And Loans Receivable Noncurrent AllowanceForNotesAndLoansReceivableNoncurrent	4449000	usd
CY2024Q1	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	23287000	usd
CY2023Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	24832000	usd
CY2024Q1	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	430427000	usd
CY2023Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	408341000	usd
CY2024Q1	us-gaap	Financing Receivable Nonaccrual Interest Income FinancingReceivableNonaccrualInterestIncome	1100000	usd
CY2023Q1	us-gaap	Financing Receivable Nonaccrual Interest Income FinancingReceivableNonaccrualInterestIncome	600000	usd
CY2024Q1	hcsg	Financing Receivable Allowance For Credit Loss Writeoff Year One Originated Current Fiscal Year FinancingReceivableAllowanceForCreditLossWriteoffYearOneOriginatedCurrentFiscalYear	0	usd
CY2024Q1	hcsg	Financing Receivable Allowance For Credit Loss Writeoff Year Two Originated Fiscal Year Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossWriteoffYearTwoOriginatedFiscalYearBeforeCurrentFiscalYear	0	usd
CY2024Q1	hcsg	Financing Receivable Allowance For Credit Loss Writeoff Year Three Originated Two Years Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossWriteoffYearThreeOriginatedTwoYearsBeforeCurrentFiscalYear	0	usd
CY2024Q1	hcsg	Financing Receivable Allowance For Credit Loss Writeoff Year Four Originated Three Years Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossWriteoffYearFourOriginatedThreeYearsBeforeCurrentFiscalYear	0	usd
CY2024Q1	hcsg	Financing Receivable Allowance For Credit Loss Writeoff Year Five Originated Four Years Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossWriteoffYearFiveOriginatedFourYearsBeforeCurrentFiscalYear	0	usd
CY2024Q1	hcsg	Financing Receivable Allowance For Credit Loss Writeoff Originated More Than Five Years Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossWriteoffOriginatedMoreThanFiveYearsBeforeCurrentFiscalYear	0	usd
CY2024Q1	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	0	usd
CY2024Q1	hcsg	Financing Receivable Allowance For Credit Loss Recovery Year One Originated Current Fiscal Year FinancingReceivableAllowanceForCreditLossRecoveryYearOneOriginatedCurrentFiscalYear	0	usd
CY2024Q1	hcsg	Financing Receivable Allowance For Credit Loss Recovery Year Two Originated Fiscal Year Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossRecoveryYearTwoOriginatedFiscalYearBeforeCurrentFiscalYear	0	usd
CY2024Q1	hcsg	Financing Receivable Allowance For Credit Loss Recovery Year Three Originated Two Years Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossRecoveryYearThreeOriginatedTwoYearsBeforeCurrentFiscalYear	0	usd
CY2024Q1	hcsg	Financing Receivable Allowance For Credit Loss Recovery Year Four Originated Three Years Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossRecoveryYearFourOriginatedThreeYearsBeforeCurrentFiscalYear	0	usd
CY2024Q1	hcsg	Financing Receivable Allowance For Credit Loss Recovery Year Five Originated Four Years Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossRecoveryYearFiveOriginatedFourYearsBeforeCurrentFiscalYear	0	usd
CY2024Q1	hcsg	Financing Receivable Allowance For Credit Loss Recovery Originated More Than Five Years Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossRecoveryOriginatedMoreThanFiveYearsBeforeCurrentFiscalYear	0	usd
CY2024Q1	us-gaap	Financing Receivable Allowance For Credit Losses Recovery FinancingReceivableAllowanceForCreditLossesRecovery	0	usd
CY2024Q1	hcsg	Financing Receivable Allowance For Credit Loss Writeoff After Recovery Year One Originated Current Fiscal Year FinancingReceivableAllowanceForCreditLossWriteoffAfterRecoveryYearOneOriginatedCurrentFiscalYear	0	usd
CY2024Q1	hcsg	Financing Receivable Allowance For Credit Loss Writeoff After Recovery Year Two Originated Fiscal Year Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossWriteoffAfterRecoveryYearTwoOriginatedFiscalYearBeforeCurrentFiscalYear	0	usd
CY2024Q1	hcsg	Financing Receivable Allowance For Credit Loss Writeoff After Recovery Year Three Originated Two Years Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossWriteoffAfterRecoveryYearThreeOriginatedTwoYearsBeforeCurrentFiscalYear	0	usd
CY2024Q1	hcsg	Financing Receivable Allowance For Credit Loss Writeoff After Recovery Year Four Originated Three Years Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossWriteoffAfterRecoveryYearFourOriginatedThreeYearsBeforeCurrentFiscalYear	0	usd
CY2024Q1	hcsg	Financing Receivable Allowance For Credit Loss Writeoff After Recovery Year Five Originated Four Years Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossWriteoffAfterRecoveryYearFiveOriginatedFourYearsBeforeCurrentFiscalYear	0	usd
CY2024Q1	hcsg	Financing Receivable Allowance For Credit Loss Writeoff After Recovery Originated More Than Five Years Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossWriteoffAfterRecoveryOriginatedMoreThanFiveYearsBeforeCurrentFiscalYear	0	usd
CY2024Q1	us-gaap	Financing Receivable Allowance For Credit Loss Writeoff After Recovery FinancingReceivableAllowanceForCreditLossWriteoffAfterRecovery	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	80819000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	1033000	usd
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	4301000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	84087000	usd
CY2023Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	10880000	usd
CY2024Q1	us-gaap	Financing Receivable Allowance For Credit Loss Writeoff After Recovery FinancingReceivableAllowanceForCreditLossWriteoffAfterRecovery	0	usd
CY2024Q1	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	620000	usd
CY2024Q1	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	11500000	usd
CY2023Q4	us-gaap	Accounts And Financing Receivable Allowance For Credit Loss AccountsAndFinancingReceivableAllowanceForCreditLoss	91699000	usd
CY2024Q1	hcsg	Accounts And Financing Receivable Allowance For Credit Loss Writeoff AccountsAndFinancingReceivableAllowanceForCreditLossWriteoff	1033000	usd
CY2024Q1	hcsg	Accounts And Financing Receivable Credit Loss Expense Reversal AccountsAndFinancingReceivableCreditLossExpenseReversal	4921000	usd
CY2024Q1	us-gaap	Accounts And Financing Receivable Allowance For Credit Loss AccountsAndFinancingReceivableAllowanceForCreditLoss	95587000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	100000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	66601000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	3453000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	5259000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	68407000	usd
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	6863000	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Loss Writeoff After Recovery FinancingReceivableAllowanceForCreditLossWriteoffAfterRecovery	51000	usd
CY2023Q1	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	1648000	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	8460000	usd
CY2022Q4	us-gaap	Accounts And Financing Receivable Allowance For Credit Loss AccountsAndFinancingReceivableAllowanceForCreditLoss	73464000	usd
CY2023Q1	hcsg	Accounts And Financing Receivable Allowance For Credit Loss Writeoff AccountsAndFinancingReceivableAllowanceForCreditLossWriteoff	3504000	usd
CY2023Q1	hcsg	Accounts And Financing Receivable Credit Loss Expense Reversal AccountsAndFinancingReceivableCreditLossExpenseReversal	6907000	usd
CY2023Q1	us-gaap	Accounts And Financing Receivable Allowance For Credit Loss AccountsAndFinancingReceivableAllowanceForCreditLoss	76867000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	100000	usd
CY2024Q1	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	-495000	usd
CY2023Q1	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	1206000	usd
CY2024Q1	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-167000	usd
CY2023Q1	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-1000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-328000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1207000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	200000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	100000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	-100000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	300000	usd
CY2024Q1	hcsg	Operating Lease Right Of Use Asset Before Accumulated Amortization OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization	28005000	usd
CY2023Q4	hcsg	Operating Lease Right Of Use Asset Before Accumulated Amortization OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization	27099000	usd
CY2024Q1	hcsg	Property Plant And Equipment And Operating Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	52745000	usd
CY2023Q4	hcsg	Property Plant And Equipment And Operating Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	50803000	usd
CY2024Q1	hcsg	Property Plant And Equipment And Operating Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	23555000	usd
CY2023Q4	hcsg	Property Plant And Equipment And Operating Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	22029000	usd
CY2024Q1	hcsg	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	29190000	usd
CY2023Q4	hcsg	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	28774000	usd
CY2024Q1	hcsg	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	10400000	usd
CY2023Q4	hcsg	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	9400000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	2900000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	2500000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1800000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1200000	usd
CY2024Q1	hcsg	Lessee Operating Lease Termination Option Term LesseeOperatingLeaseTerminationOptionTerm	P1Y
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1837000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1387000	usd
CY2024Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	171000	usd
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	232000	usd
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	290000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	450000	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	2298000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	2069000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1911000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1514000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y1M6D
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.067
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.051
CY2024Q1	hcsg	Right Of Use Asset And Operating Lease Liability Decrease Due To Cancellation RightOfUseAssetAndOperatingLeaseLiabilityDecreaseDueToCancellation	100000	usd
CY2023Q1	hcsg	Right Of Use Asset And Operating Lease Liability Decrease Due To Cancellation RightOfUseAssetAndOperatingLeaseLiabilityDecreaseDueToCancellation	700000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	5769000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	7080000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4252000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1469000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1389000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	116000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	20075000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1918000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	18157000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2014000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2685000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2666000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1196000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	613000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	508000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1774000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	700000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1200000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-300000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1200000	usd
CY2024Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-700000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	300000	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	16600000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	200000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	200000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	100000	usd
CY2024Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain EquitySecuritiesFvNiUnrealizedGain	4100000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain EquitySecuritiesFvNiUnrealizedGain	1500000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	78368000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	204000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2954000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	75618000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	95466000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	387000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2722000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	93131000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	1025000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	6324000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	25371000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	34939000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	37006000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	39309000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	12216000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	12559000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	75618000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	93131000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2484000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2058000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2484000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2058000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	24800000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y3M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2438000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.43
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	290000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.36
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	172000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	28.13
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2556000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	28.31
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.06
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.53
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.039
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.040
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y10M24D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.405
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.395
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	614000	usd
CY2024Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P5Y2M12D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1763000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	33.94
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y3M18D
CY2024Q1	us-gaap	Line Of Credit LineOfCredit	40000000	usd
CY2024Q1	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1000000	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	900000	usd
CY2024Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2689000	shares
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	423433000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	417230000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	21314000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	16155000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	15309000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	11671000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73926000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74497000	shares
CY2024Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	129000	shares
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	21000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74055000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74518000	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.21
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.16
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.21
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.16
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3191000	shares
CY2024Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	300000000	usd
CY2023Q4	us-gaap	Line Of Credit LineOfCredit	25000000	usd
CY2024Q1	hcsg	Debt Instrument Covenant Number DebtInstrumentCovenantNumber	2	covenant
CY2024Q1	hcsg	Lineof Credit Facility Increase Decrease Remaining Borrowing Capacity LineofCreditFacilityIncreaseDecreaseRemainingBorrowingCapacity	-72400000	usd
CY2024Q1	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	187600000	usd
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0000731012-24-000065-index-headers.html	Edgar Link	pending
0000731012-24-000065-index.html	Edgar Link	pending
0000731012-24-000065.txt	Edgar Link	pending
0000731012-24-000065-xbrl.zip	Edgar Link	pending
ex311section302certificati.htm	Edgar Link	pending
ex312section302certificati.htm	Edgar Link	pending
ex321section906certificati.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hcsg-20240331.htm	Edgar Link	pending
hcsg-20240331.xsd	Edgar Link	pending
hcsg-20240331_g1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
hcsg-20240331_cal.xml	Edgar Link	unprocessable
hcsg-20240331_def.xml	Edgar Link	unprocessable
hcsg-20240331_lab.xml	Edgar Link	unprocessable
hcsg-20240331_pre.xml	Edgar Link	unprocessable
hcsg-20240331_htm.xml	Edgar Link	completed
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HCSG
HEALTHCARE SERVICES GROUP INC Stock $hcsg

2024 Q2 Form 10-Q Financial Statement

#000073101224000065 Filed on April 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCSG HEALTHCARE SERVICES GROUP INC Stock $hcsg

2024 Q2 Form 10-Q Financial Statement

#000073101224000065 Filed on April 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCSG
HEALTHCARE SERVICES GROUP INC Stock $hcsg